降圧剤市場：薬剤クラス別、剤形別、適応症別、流通チャネル別、エンドユーザー別-2025-2030年の世界予測

降圧剤市場の2023年の市場規模は247億米ドルで、2024年には257億6,000万米ドルに達すると予測され、CAGR 4.66%で成長し、2030年には339億9,000万米ドルに達すると予測されています。

降圧剤の市場は、利尿薬、ACE阻害薬、カルシウム拮抗薬、ARBなど、高血圧とそれに関連する心血管疾患の管理を目的とした複数のクラスの薬剤を包含する広範な市場であることが特徴です。高血圧はしばしば「サイレント・キラー」と呼ばれ、その蔓延と深刻な健康への影響の可能性から、これらの薬剤の適用が必要とされ、世界中のヘルスケア戦略に不可欠なものとなっています。最終用途は主に病院、診療所、在宅医療に及んでおり、さまざまな患者層に幅広く適用されていることがわかる。成長に影響を与える主な要因としては、人口動態の変化、ライフスタイルの変化、心血管の健康に対する意識の高まりによる高血圧の罹患率の増加が挙げられます。高齢者は高血圧になりやすいため、世界人口の高齢化は大きな促進要因となっています。ドラッグ製剤やドラッグデリバリーの技術的進歩も市場拡大に拍車をかけています。個別化医療には新たなビジネスチャンスが存在し、薬理ゲノミクスによって個々の遺伝子プロファイルに合わせたより効果的な降圧レジメンが導かれる可能性があります。さらに、新興国市場でのヘルスケアアクセスの拡大も市場開拓の大きなチャンスとなります。しかし、降圧剤に伴う副作用や、医薬品承認に関わる厳しい規制状況などの制約が市場成長の妨げとなる可能性があります。また、特許医薬品のジェネリックへの侵食や、生活習慣への介入やホリスティックなアプローチを含む代替療法との競合も課題となっています。技術革新が必要な分野としては、副作用を最小限に抑えながら有効性を高める併用療法の開発や、ナノ粒子などの新規ドラッグデリバリーシステムの活用が挙げられます。さらに、耐性メカニズムを解明する調査により、薬剤反応性を改善する画期的な治療法が生まれる可能性もあります。降圧剤市場は、臨床需要、技術革新、経済的要因に牽引されるダイナミックな市場であり、今後の成長は、規制状況の克服、患者のコンプライアンス問題への対応、薬効とアクセシビリティを向上させる技術の進歩の活用にかかっています。

市場力学：急速に進化する降圧剤市場の主要市場インサイトを公開

降圧剤市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢者人口の増加に伴う高血圧有病率の急増
  • 世界のヘルスケア支出の増加
  • 早期診断・治療に対する消費者の意識の高まり
• 市場抑制要因
  • 厳しい承認プロセスと医薬品開発にかかる莫大なコスト
• 市場機会
  • 新しいクラスの降圧剤のイントロダクション
  • 規制当局による新薬承認の急増
• 市場の課題
  • 降圧剤による健康被害への懸念

ポーターの5つの力：降圧剤市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：降圧剤市場における外部からの影響の把握

外部マクロ環境要因は、降圧剤市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析降圧剤市場における競合情勢の把握

降圧剤市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス降圧剤市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、降圧剤市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨降圧剤市場における成功への道筋を描く

降圧剤市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高血圧の有病率の急増と高齢者人口の増加
    • 世界中でヘルスケア費が増加
    • 早期診断と治療に対する消費者の意識の高まり
  • 抑制要因
    • 医薬品開発には厳格な承認プロセスと莫大なコストがかかる
  • 機会
    • 新しいクラスの降圧剤のイントロダクション
    • 規制当局による新薬承認の急増
  • 課題
    • 降圧剤の健康への悪影響に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 降圧剤市場薬剤クラス別

• アルファ遮断薬
• アンジオテンシン変換酵素阻害剤
• アンジオテンシン受容体遮断薬
• ベータ遮断薬
• カルシウムチャネル遮断薬
• 利尿剤
• レニン阻害剤
• 血管拡張薬

第7章 降圧剤市場：形態別

• 静脈注射
• 経口錠剤/カプセル
• 経皮パッチ

第8章 降圧剤市場適応症別

• 原発性高血圧
• 二次性高血圧

第9章 降圧剤市場：流通チャネル別

• オフライン
• オンライン

第10章 降圧剤市場：エンドユーザー別

• 在宅介護施設
• 病院・クリニック

第11章 南北アメリカの降圧剤市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の降圧剤市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの降圧剤市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alembic Pharmaceuticals Limited
• Alkem Laboratories
• Apikos Pharma
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Centurion Remedies Private Limited
• Daiichi Sankyo Co., Ltd.
• Dr. Reddy's Laboratories
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson Services, Inc.
• Lupin Ltd.
• Merck & Co., Inc.
• Novartis AG
• Sanofi S.A.
• Saphnix Lifesciences
• Schwitz Biotech
• Sun Pharmaceutical Industries Limited
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• United Therapeutics Corporation
• Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. ANTIHYPERTENSIVE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIHYPERTENSIVE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIHYPERTENSIVE DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ALPHA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SECONDARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 47. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 74. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 79. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 164. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 165. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 166. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 184. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 185. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 189. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 190. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 191. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 238. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 239. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Antihypertensive Drugs Market was valued at USD 24.70 billion in 2023, expected to reach USD 25.76 billion in 2024, and is projected to grow at a CAGR of 4.66%, to USD 33.99 billion by 2030.

The market for antihypertensive drugs is characterized by a broad scope encompassing multiple classes of medications, including diuretics, ACE inhibitors, calcium channel blockers, and ARBs, aimed at managing hypertension and associated cardiovascular conditions. Hypertension, often dubbed the "silent killer," necessitates the application of these drugs due to its prevalence and potential for severe health implications, making it integral to healthcare strategies worldwide. The end-use scope primarily spans hospitals, clinics, and home healthcare settings, underscoring its extensive application among varying patient demographics. Key factors influencing growth include increasing incidences of hypertension due to demographic shifts, lifestyle changes, and heightened awareness of cardiovascular health. The aging global population is a significant driver, as older adults are more prone to high blood pressure. Technological advancements in drug formulations and delivery mechanisms also spur market expansion. Emerging opportunities exist in personalized medicine, where pharmacogenomics could guide more effective antihypertensive regimens tailored to individual genetic profiles. Furthermore, expanding healthcare access in developing regions presents a substantial opportunity for market penetration. However, limitations such as the side effects associated with antihypertensive medications and the strict regulatory landscape governing drug approval can hinder market growth. Challenges also arise from the generic erosion of patented medicines and competition from alternative therapies, including lifestyle interventions and holistic approaches. Areas ripe for innovation include the development of combination therapies that enhance efficacy while minimizing side effects and the exploitation of novel drug delivery systems such as nanoparticles. Additionally, research into understanding resistance mechanisms could lead to breakthroughs that improve drug responsiveness. The antihypertensive drug market is dynamic, driven by clinical demand, innovation, and economic factors, with future growth dependent on navigating regulatory landscapes, addressing patient compliance issues, and capitalizing on technological advances to improve drug efficacy and accessibility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antihypertensive Drugs Market

The Antihypertensive Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Surging prevalence of hypertension, along with the growing geriatric population
  • Increase in healthcare expenditure worldwide
  • Growing consumer awareness of early diagnosis and treatment
• Market Restraints
  • Stringent approval process and huge costs involved in drug development
• Market Opportunities
  • Introduction of a new class of antihypertensive drugs
  • Surge in approvals of novel drugs from regulatory bodies
• Market Challenges
  • Concern regarding adverse health outcomes of antihypertensive drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antihypertensive Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antihypertensive Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antihypertensive Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antihypertensive Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antihypertensive Drugs Market

A detailed market share analysis in the Antihypertensive Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antihypertensive Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antihypertensive Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antihypertensive Drugs Market

A strategic analysis of the Antihypertensive Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antihypertensive Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories, Apikos Pharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Centurion Remedies Private Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lupin Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Saphnix Lifesciences, Schwitz Biotech, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antihypertensive Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Alpha-Blockers, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-Blockers, Calcium Channel Blockers, Diuretics, Renin Inhibitors, and Vasodilators.
• Based on Form, market is studied across Intravenous Injections, Oral Tablets/Capsules, and Transdermal Patches.
• Based on Indication, market is studied across Primary Hypertension and Secondary Hypertension.
• Based on Distribution Channel, market is studied across Offline and Online.
• Based on End-User, market is studied across Home Care Facilities and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Surging prevalence of hypertension, along with the growing geriatric population
    • 5.1.1.2. Increase in healthcare expenditure worldwide
    • 5.1.1.3. Growing consumer awareness of early diagnosis and treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent approval process and huge costs involved in drug development
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of a new class of antihypertensive drugs
    • 5.1.3.2. Surge in approvals of novel drugs from regulatory bodies
  • 5.1.4. Challenges
    • 5.1.4.1. Concern regarding adverse health outcomes of antihypertensive drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antihypertensive Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Alpha-Blockers
• 6.3. Angiotensin Converting Enzyme Inhibitors
• 6.4. Angiotensin Receptor Blockers
• 6.5. Beta-Blockers
• 6.6. Calcium Channel Blockers
• 6.7. Diuretics
• 6.8. Renin Inhibitors
• 6.9. Vasodilators

7. Antihypertensive Drugs Market, by Form

• 7.1. Introduction
• 7.2. Intravenous Injections
• 7.3. Oral Tablets/Capsules
• 7.4. Transdermal Patches

8. Antihypertensive Drugs Market, by Indication

• 8.1. Introduction
• 8.2. Primary Hypertension
• 8.3. Secondary Hypertension

9. Antihypertensive Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Offline
• 9.3. Online

10. Antihypertensive Drugs Market, by End-User

• 10.1. Introduction
• 10.2. Home Care Facilities
• 10.3. Hospitals & Clinics

11. Americas Antihypertensive Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Antihypertensive Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Antihypertensive Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alembic Pharmaceuticals Limited
• 3. Alkem Laboratories
• 4. Apikos Pharma
• 5. AstraZeneca PLC
• 6. Bayer AG
• 7. Boehringer Ingelheim International GmbH
• 8. Centurion Remedies Private Limited
• 9. Daiichi Sankyo Co., Ltd.
• 10. Dr. Reddy's Laboratories
• 11. F. Hoffmann-La Roche AG
• 12. Gilead Sciences, Inc.
• 13. Glenmark Pharmaceuticals Ltd.
• 14. Johnson & Johnson Services, Inc.
• 15. Lupin Ltd.
• 16. Merck & Co., Inc.
• 17. Novartis AG
• 18. Sanofi S.A.
• 19. Saphnix Lifesciences
• 20. Schwitz Biotech
• 21. Sun Pharmaceutical Industries Limited
• 22. Takeda Pharmaceutical Company Limited
• 23. Teva Pharmaceutical Industries Ltd.
• 24. United Therapeutics Corporation
• 25. Zydus Lifesciences Limited